Lactobacillus gasseri

Lactobacillus gasseri is a homofermentative species native to the human oral cavity, gastrointestinal tract, and urogenital microbiota. The species is closely related to L. acidophilus and is one of the dominant native Lactobacillus species in the adult human gut.

Supplied as a freeze-dried powder with viability between 100 and 500 billion CFU per gram at release. Demonstrates strong adhesion to human intestinal epithelial cells and competitive exclusion of enteropathogens through bacteriocin (gassericin) production.

Off-white to light cream free-flowing powder with a clean fermented note. Particle size suitable for capsule, sachet, and chewable formats.

We supply food-grade Lactobacillus gasseri from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to probiotic strain production.

Common market grades include 100, 200, and 500 billion CFU per gram freeze-dried powders, heat-killed postbiotic grades, and microencapsulated formats for beverage applications. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.

Lactobacillus gasseri was first formally described in 1980 and named after the Swiss microbiologist Francois Gasser. Reference strains include ATCC 33323 and the commercial strain SBT2055 developed by Snow Brand Milk Products in Japan and now marketed by Megmilk Snow Brand.

Industrial production uses MRS-based proprietary media under anaerobic conditions, with biomass harvest, cryoprotectant blending, and lyophilization. Heat-killed (tyndallized) grades are produced by controlled thermal inactivation followed by spray drying, preserving cell-wall components and metabolites with documented biological activity.

Regulatory status includes GRAS notifications with FDA for specific strains, Qualified Presumption of Safety listing in the European Union, and acceptance for inclusion in functional foods in Japan under the Foods for Specified Health Uses (FOSHU) framework.

Clinical evidence for L. gasseri SBT2055 supports modest reductions in abdominal visceral fat in adults with elevated BMI when consumed daily for 12 weeks, with parallel evidence supporting urogenital and oral microbiome applications for other commercial strains.

• Probiotic capsules and tablets for metabolic and weight management positioning
• Women's health and vaginal microbiome supplements
• Functional yogurt and fermented dairy
• Postbiotic supplements and tyndallized cell formulations
• Capsules for adult gut microbiome restoration
• Multi-strain probiotic stacks targeting metabolic health
• Oral health and dental probiotic formulations
• Pediatric and adolescent supplements
• Synbiotic formulations with prebiotic fibers